These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 32210536

  • 1. Review on the Structures and Activities of Transthyretin Amyloidogenesis Inhibitors.
    Guo X, Liu Z, Zheng Y, Li Y, Li L, Liu H, Chen Z, Wu L.
    Drug Des Devel Ther; 2020; 14():1057-1081. PubMed ID: 32210536
    [Abstract] [Full Text] [Related]

  • 2. The discovery and development of transthyretin amyloidogenesis inhibitors: what are the lessons?
    Zhong B, Huang X, Zheng Y, Guo X, Wu L.
    Future Med Chem; 2021 Dec; 13(23):2083-2105. PubMed ID: 34633220
    [Abstract] [Full Text] [Related]

  • 3. Uncovering the Mechanism of Aggregation of Human Transthyretin.
    Saelices L, Johnson LM, Liang WY, Sawaya MR, Cascio D, Ruchala P, Whitelegge J, Jiang L, Riek R, Eisenberg DS.
    J Biol Chem; 2015 Nov 27; 290(48):28932-43. PubMed ID: 26459562
    [Abstract] [Full Text] [Related]

  • 4. A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.
    Choi S, Reixach N, Connelly S, Johnson SM, Wilson IA, Kelly JW.
    J Am Chem Soc; 2010 Feb 03; 132(4):1359-70. PubMed ID: 20043671
    [Abstract] [Full Text] [Related]

  • 5. Novel transthyretin amyloid fibril formation inhibitors: synthesis, biological evaluation, and X-ray structural analysis.
    Palaninathan SK, Mohamedmohaideen NN, Orlandini E, Ortore G, Nencetti S, Lapucci A, Rossello A, Freundlich JS, Sacchettini JC.
    PLoS One; 2009 Jul 21; 4(7):e6290. PubMed ID: 19621084
    [Abstract] [Full Text] [Related]

  • 6. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
    Green NS, Palaninathan SK, Sacchettini JC, Kelly JW.
    J Am Chem Soc; 2003 Nov 05; 125(44):13404-14. PubMed ID: 14583036
    [Abstract] [Full Text] [Related]

  • 7. Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state.
    Petrassi HM, Johnson SM, Purkey HE, Chiang KP, Walkup T, Jiang X, Powers ET, Kelly JW.
    J Am Chem Soc; 2005 May 11; 127(18):6662-71. PubMed ID: 15869287
    [Abstract] [Full Text] [Related]

  • 8. Crown Ethers as Transthyretin Amyloidogenesis Inhibitors.
    Yokoyama T, Mizuguchi M.
    J Med Chem; 2019 Feb 28; 62(4):2076-2082. PubMed ID: 30688456
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Transthyretin Amyloidogenesis Inhibitors: From Discovery to Current Developments.
    Yokoyama T, Mizuguchi M.
    J Med Chem; 2020 Dec 10; 63(23):14228-14242. PubMed ID: 32914975
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Crystallographic study of novel transthyretin ligands exhibiting negative-cooperativity between two thyroxine binding sites.
    Tomar D, Khan T, Singh RR, Mishra S, Gupta S, Surolia A, Salunke DM.
    PLoS One; 2012 Dec 10; 7(9):e43522. PubMed ID: 22973437
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Nearly 200 X-ray crystal structures of transthyretin: what do they tell us about this protein and the design of drugs for TTR amyloidoses?
    Palaninathan SK.
    Curr Med Chem; 2012 Dec 10; 19(15):2324-42. PubMed ID: 22471981
    [Abstract] [Full Text] [Related]

  • 16. Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
    Connelly S, Mortenson DE, Choi S, Wilson IA, Powers ET, Kelly JW, Johnson SM.
    Bioorg Med Chem Lett; 2017 Aug 01; 27(15):3441-3449. PubMed ID: 28625364
    [Abstract] [Full Text] [Related]

  • 17. Amyloid disease prevention by transthyretin native state complexation with carborane derivatives lacking cyclooxygenase inhibition.
    Julius RL, Hawthorne MF.
    Drug News Perspect; 2008 Jun 01; 21(5):258-66. PubMed ID: 18596990
    [Abstract] [Full Text] [Related]

  • 18. R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression.
    Sekijima Y, Dendle MT, Wiseman RL, White JT, D'Haeze W, Kelly JW.
    Amyloid; 2006 Jun 01; 13(2):57-66. PubMed ID: 16911959
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.
    Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, Powers ET, Wiseman RL, Foss TR, Wilson IA, Kelly JW, Labaudinière R.
    Proc Natl Acad Sci U S A; 2012 Jun 12; 109(24):9629-34. PubMed ID: 22645360
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.